Cue Health Selected by Minnesota Department of Health to Provide Statewide Telehealth to Treatment Services to all Minnesota Residents at No Cost
December 22 2022 - 4:15PM
Business Wire
In partnership with Minnesota Department of
Health, Cue’s digital service offers an integrated solution to
provide COVID-19 treatment options access across all
populations
Cue Health (“Cue”) (Nasdaq: HLTH), the
healthcare technology company known for diagnostic enabled care,
today announced that it has been selected by Minnesota Department
of Health (MDH) to provide a statewide COVID-19 telehealth to
treatment program, powered by Cue Care™, at no cost to Minnesota
residents.
With Cue, Minnesotans who test positive on any COVID-19 self
test can consult virtually and on-demand with a healthcare
professional to obtain a prescription for COVID-19 treatment at no
cost, if they are medically indicated. Through the program,
COVID-19 treatment is made available for same day pick-up or
delivery from a local pharmacy. Cue’s telehealth to treatment
services offered in partnership with MDH will be accessible at no
cost to all Minnesota residents regardless of insurance status via
mobile, web, and telephone.
“Cue’s diagnostic platform has been deployed over the past two
years across the United States, including in Minnesota, and we are
proud to expand our partnership with the State to now provide
Minnesotans access to our telehealth to treatment services for
COVID-19,” said Chris Achar, Chief Strategy Officer for Cue Health.
“Our solution builds on Cue’s history of successful public sector
work and can be utilized in the future to address other important
public health issues, such as influenza and sexually transmitted
infections.”
Cue’s collaboration with the State of Minnesota began in 2020
when, as part of the Departments of Defense and Health and Human
Services’ pandemic response programs, Cue began delivering Cue
Health Monitoring Systems and Cue COVID-19 molecular tests to the
State, which were deployed across critical settings.
Cue’s COVID-19 test was the first molecular diagnostic test
available to consumers without a prescription and is the most
accurate at-home COVID-19 test*, delivering results in 20 minutes
to connected mobile devices. It detects all known COVID-19 variants
of concern in people with or without symptoms. Cue is used in
homes, in point-of-care settings, and by world-class organizations
across the country, including Mayo Clinic, Johns Hopkins Medicine,
Google, the National Basketball Association, and Major League
Baseball, among many others.
An independent study by Mayo Clinic, released in 2021, found
Cue's COVID-19 test showed 97.8% concordance with central lab PCR
tests.
The telehealth-to-treatment service in Minnesota is currently
available through the Cue Health App on the Apple App Store and
through Google Play for Android devices.
*#1 accuracy claim based on comparison of clinical study results
submitted to the U.S. Food and Drug Administration (FDA) for
Emergency Use Authorization for Cue and other molecular home
tests.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easier for individuals to access health information
and places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United States, Cue Health has received the
CE mark in the European Union, Interim Order authorization from
Health Canada, regulatory approval from India's Central Drugs
Standard Control Organization, and PSAR authorization from
Singapore’s Health Sciences Authority. Cue was founded in 2010 and
is headquartered in San Diego. For more information, please visit
www.cuehealth.com.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements”. The words, without limitation,
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including those related to the expected future diagnostic
test menu and the factors discussed in the “Risk Factors” section
of Cue’s Annual Report on Form 10-K for the year ended December 31,
2021 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2022 filed with the SEC on November 9, 2022. Any
forward-looking statements contained in this press release are
based on the current expectations of Cue’s management team and
speak only as of the date hereof, and Cue specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Cue’s COVID-19 tests have not been FDA cleared or approved; but
have been authorized by FDA and under an Emergency Use
Authorization (EUA). These products have been authorized only for
the detection of nucleic acid from SARS-CoV-2, not for any other
viruses or pathogens. The emergency use of these products is only
authorized for the duration of the declaration that circumstances
exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221222005391/en/
MEDIA INQUIRIES press@cuehealth.com
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jul 2023 to Jul 2024